Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Capoxigem; CS-706; Kymena; R-109339; TG 01; TP1001 programme; TP2001 programme

Latest Information Update: 04 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Tragara Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Inflammation; Inflammatory pain; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 03 Jan 2019 Tragara Pharmaceuticals is now called Adastra Pharmaceuticals
  • 24 Jun 2018 Biomarkers information updated
  • 09 Jul 2015 Tragara Pharmaceuticals completes a phase II trial in Non-small cell lung cancer (Combination therapy, late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT00771953)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top